Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcabene in Adults With Familial Partial Lipodystrophy (FPLD)
NCT03508687Phase 2Completed
- Start
- Mar 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcabene in familial partial lipodystrophy (FPLD) (2 arms). Primary endpoint: Change in Fasting Serum Triglyceride at 12 weeks. Started Mar 2018; status: completed.
02
Drugs
gemcabene
03
Conditions
familial partial lipodystrophy (FPLD)
Beyond the preview
Go deeper on NCT03508687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03508687.